Cardio Net Debt from 2010 to 2026
| CDIO Stock | USD 1.51 0.09 5.63% |
Net Debt | First Reported 2010-12-31 | Previous Quarter -6.2 M | Current Value -5.9 M | Quarterly Volatility 2.4 M |
Check Cardio Diagnostics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cardio Diagnostics' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Depreciation And Amortization of 333.7 K or Selling General Administrative of 9.9 M, as well as many indicators such as Price To Sales Ratio of 23.2 K, Dividend Yield of 0.0 or PTB Ratio of 84.57. Cardio financial statements analysis is a perfect complement when working with Cardio Diagnostics Valuation or Volatility modules.
Cardio | Net Debt | Build AI portfolio with Cardio Stock |
Evaluating Cardio Diagnostics's Net Debt across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Cardio Diagnostics Holdings's fundamental strength.
Latest Cardio Diagnostics' Net Debt Growth Pattern
Below is the plot of the Net Debt of Cardio Diagnostics Holdings over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. Cardio Diagnostics' Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cardio Diagnostics' overall financial position and show how it may be relating to other accounts over time.
| Net Debt | 10 Years Trend |
|
Net Debt |
| Timeline |
Cardio Net Debt Regression Statistics
| Arithmetic Mean | (1,488,498) | |
| Coefficient Of Variation | (162.31) | |
| Mean Deviation | 1,906,736 | |
| Median | (237,087) | |
| Standard Deviation | 2,416,039 | |
| Sample Variance | 5.8T | |
| Range | 6.8M | |
| R-Value | (0.71) | |
| Mean Square Error | 3.1T | |
| R-Squared | 0.50 | |
| Significance | 0 | |
| Slope | (338,617) | |
| Total Sum of Squares | 93.4T |
Cardio Net Debt History
Other Fundumenentals of Cardio Diagnostics
Cardio Diagnostics Net Debt component correlations
Click cells to compare fundamentals
About Cardio Diagnostics Financial Statements
Cardio Diagnostics investors utilize fundamental indicators, such as Net Debt, to predict how Cardio Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Debt | -6.2 M | -5.9 M | |
| Net Debt To EBITDA | 0.76 | 0.45 |
Pair Trading with Cardio Diagnostics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cardio Diagnostics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cardio Diagnostics will appreciate offsetting losses from the drop in the long position's value.Moving together with Cardio Stock
Moving against Cardio Stock
| 0.82 | IPSC | Century Therapeutics | PairCorr |
| 0.8 | FHTX | Foghorn Therapeutics | PairCorr |
| 0.79 | HOOK | Hookipa Pharma | PairCorr |
| 0.7 | IVA | Inventiva Sa | PairCorr |
| 0.7 | GMAB | Genmab AS | PairCorr |
The ability to find closely correlated positions to Cardio Diagnostics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cardio Diagnostics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cardio Diagnostics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cardio Diagnostics Holdings to buy it.
The correlation of Cardio Diagnostics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cardio Diagnostics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cardio Diagnostics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cardio Diagnostics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Cardio Diagnostics Correlation against competitors. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Will Biotechnology sector continue expanding? Could Cardio diversify its offerings? Factors like these will boost the valuation of Cardio Diagnostics. Projected growth potential of Cardio fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Cardio Diagnostics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (11.91) | Revenue Per Share | Quarterly Revenue Growth (0.57) | Return On Assets | Return On Equity |
Cardio Diagnostics's market price often diverges from its book value, the accounting figure shown on Cardio's balance sheet. Smart investors calculate Cardio Diagnostics' intrinsic value—its true economic worth—which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Cardio Diagnostics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Cardio Diagnostics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cardio Diagnostics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Cardio Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.